Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thromboembolism in children.

Ulrike Nowak-Göttl1, Andrea Kosch, Nicole Schlegel

  • 1Department of Pediatric Hematology/Oncology, University of Münster, Germany. leagottl@uni-muenster.de

Current Opinion in Hematology
|August 13, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Haemophilia Joint Health Score Ranges Across the Lifespan: Variation by Haemophilia Type and Severity.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Persons with high Hemophilia Joint Health Scores have reduced functional range of motion during simulated sports activities.

Research and practice in thrombosis and haemostasis·2026
Same author

Corrigendum to "Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels".

Journal of thrombosis and haemostasis : JTH·2026
Same author

Corrigendum to 'Real-world use of protein C concentrate for the treatment of patients with protein C deficiency: an international registry': [Journal of Thrombosis and Haemostasis 23(11) (2025) 3569-3577].

Journal of thrombosis and haemostasis : JTH·2025
Same author

Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction.

Nature genetics·2025
Same author

Real-world use of protein C concentrate for the treatment of patients with protein C deficiency: an international registry.

Journal of thrombosis and haemostasis : JTH·2025
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Pediatric thromboembolism risk rises with acquired and inherited prothrombotic factors. Screening for gene mutations and deficiencies aids diagnosis and management, adapting adult treatment protocols for children.

Area of Science:

  • Pediatric Hematology
  • Thrombosis and Hemostasis
  • Genetics

Background:

  • Acquired and inherited prothrombotic risk factors are significant contributors to pediatric thrombosis.
  • Understanding these factors is crucial for effective diagnosis and management in children.

Purpose of the Study:

  • To review current literature on prothrombotic risk factors, diagnostic imaging, and treatment for pediatric thromboembolism.
  • To highlight key genetic mutations and deficiencies relevant to pediatric thrombophilia.

Main Methods:

  • Literature review of pediatric reports and new data (January 2001-February 2002).
  • Focus on imaging modalities for thromboembolism confirmation.
  • Analysis of genetic screening protocols for common and rare thrombophilias.

Related Experiment Videos

Main Results:

  • Common gene mutations (factor V G1691A, prothrombin G20210A, MTHFR C677T) and rare deficiencies (protein C, S, antithrombin, plasminogen) are key targets.
  • Emerging genetic factors include lipoprotein(a), homocysteine, fibrinogen, and coagulation factors.
  • Interpretation requires age-dependent ranges and ethnic considerations.

Conclusions:

  • Screening pediatric patients with confirmed thromboembolism for genetic risk factors is recommended.
  • Treatment protocols for pediatric acute thromboembolism are largely based on adult guidelines.
  • Further research may refine pediatric-specific diagnostic and therapeutic approaches.